CHILDS JOHN W 4
4 · Veradermics, Inc · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Veradermics (MANE) Director John W. Childs Buys $5M; Prefs Convert
What Happened
John W. Childs, a member of Veradermics' board of directors, acquired 294,117 shares in a private/open-market purchase on February 5, 2026 at $17.00 per share for a total of $4,999,989. On the same day, three series of the company's convertible preferred stock automatically converted into common stock immediately prior to the closing of the company’s initial public offering: Series A, B and C converted on a 10.067-for-1 basis, resulting in the issuance of 480,269, 906,862 and 520,758 common shares respectively (totaling 1,907,889 common shares). In addition, on February 3, 2026 Childs was reported as having been granted 51,525 derivative shares (an award/option) with an exercise/vesting profile noted in the filing.
Key Details
- Transaction dates: Feb 3, 2026 (award grant of 51,525 derivative shares); Feb 5, 2026 (open-market/private purchase and automatic conversions).
- Purchase: 294,117 shares at $17.00 each = $4,999,989 total.
- Automatic conversions: Series A → 480,269 shares; Series B → 906,862 shares; Series C → 520,758 shares (all converted on a 10.067-for-1 basis with no additional consideration).
- Grant: 51,525 derivative shares reported at $0.00; filing notes this option/award will be fully vested and exercisable on Feb 3, 2027.
- Shares owned after transaction: not specified in the filing.
- Ownership/beneficial notes: Some shares are held by J.W. Childs Associates (FL), L.P., which is owned by the John W. Childs 2013 Revocable Trust; as trustee Childs may be deemed to hold voting/dispositive power over those holdings.
Context
- The conversion entries reflect automatic conversions of preferred stock into common stock immediately prior to the IPO, not a cash transaction — the filing lists the preferred as disposed and common as acquired as part of that process.
- The $5.0M open-market/private purchase is a direct purchase by/for the insider and is typically seen as a more informative (bullish) signal than routine sales, though filings do not state motivation.
- The awarded 51,525 derivative shares are subject to vesting/exercise rules (fully exercisable one year after vesting commencement per the filing).
All items are reported facts from the Form 4 (Accession 0001628280-26-005906). This summary is informational and does not imply investment advice.
Insider Transaction Report
- Conversion
Common Stock
[F1][F2]2026-02-05+480,269→ 480,269 total(indirect: See Footnote) - Conversion
Common Stock
[F3][F2]2026-02-05+906,862→ 1,387,131 total(indirect: See Footnote) - Conversion
Common Stock
[F4][F2]2026-02-05+520,758→ 1,907,889 total(indirect: See Footnote) - Purchase
Common Stock
[F2]2026-02-05$17.00/sh+294,117$4,999,989→ 2,202,006 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
[F1][F2]2026-02-05−480,269→ 0 total(indirect: See Footnote)→ Common Stock (480,269 underlying) - Conversion
Series B Convertible Preferred Stock
[F3][F2]2026-02-05−906,862→ 0 total(indirect: See Footnote)→ Common Stock (906,862 underlying) - Conversion
Series C Convertible Preferred Stock
[F4][F2]2026-02-05−520,758→ 0 total(indirect: See Footnote)→ Common Stock (520,758 underlying) - Award
Stock Option (Right to Buy)
[F5]2026-02-03+51,525→ 51,525 totalExercise: $17.00Exp: 2036-02-03→ Common Stock (51,525 underlying)
Footnotes (5)
- [F1]On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
- [F3]On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F4]On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F5]This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.